Jupiter Neurosciences Company Insiders
| JUNS Stock | USD 1.01 0.01 0.98% |
Jupiter Neurosciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Jupiter Neurosciences Common stock suggests that vertually all insiders are extremely bullish at this time. Jupiter Neurosciences employs about 4 people. The company is managed by 7 executives with a total tenure of roughly 10 years, averaging almost 1.0 years of service per executive, having 0.57 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2025-07-01 | Alison D Silva | Acquired 750 @ 1.03 | View | ||
| 2025-06-30 | Alison D Silva | Acquired 950 @ 1.03 | View | ||
| 2025-06-27 | Alison D Silva | Acquired 850 @ 1.03 | View |
Monitoring Jupiter Neurosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jupiter Neurosciences Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. Jupiter Neurosciences Management Team Effectiveness
The company has return on total asset (ROA) of (3.5494) % which means that it has lost $3.5494 on every $100 spent on assets. This is way below average. Jupiter Neurosciences' management efficiency ratios could be used to measure how well Jupiter Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2026. Return On Capital Employed is likely to gain to -0.81 in 2026. At this time, Jupiter Neurosciences' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 1.9 M in 2026, whereas Debt To Assets are likely to drop 0.04 in 2026.Common Stock Shares Outstanding is likely to drop to about 22.3 M in 2026Jupiter Neurosciences Common has a total of 34.43 Million outstanding shares. Jupiter Neurosciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Jupiter Neurosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Jupiter Neurosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Jupiter Neurosciences Workforce Comparison
Jupiter Neurosciences Common is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 662. Jupiter Neurosciences maintains roughly 4.0 in number of employees contributing less than 1% to equities under Health Care industry.
Jupiter Neurosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jupiter Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jupiter Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Jupiter Neurosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wahlestedt Claes Robert over a month ago Insider Trading | ||
Elmasri Saleem over six months ago Acquisition by Elmasri Saleem of 66293 shares of Jupiter Neurosciences, subject to Rule 16b-3 | ||
Silva Alison D. over six months ago Acquisition by Silva Alison D. of 255320 shares of Jupiter Neurosciences, at 1.19 subject to Rule 16b-3 | ||
Alexander Rosen over six months ago Insider Trading | ||
Christer Rosen over six months ago Insider Trading | ||
Brady Allison W over six months ago Disposition of 21750 shares by Brady Allison W of Jupiter Neurosciences, at 2.8 subject to Rule 16b-3 | ||
Marshall Hayward over six months ago Insider Trading |
Jupiter Neurosciences Notable Stakeholders
A Jupiter Neurosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Jupiter Neurosciences often face trade-offs trying to please all of them. Jupiter Neurosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Jupiter Neurosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Marshall Hayward | Chief CoFounder | Profile | |
| Shaun Brothers | Consulting CoFounder | Profile | |
| Alexander Rosen | CoFounder Officer | Profile | |
| Christer Rosen | CEO CoFounder | Profile | |
| Claes MD | CoChairman CoFounder | Profile | |
| MS MA | Chief President | Profile | |
| Saleem CPA | CFO Secretary | Profile |
About Jupiter Neurosciences Management Performance
The success or failure of an entity such as Jupiter Neurosciences often depends on how effective the management is. Jupiter Neurosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Jupiter management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Jupiter management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.85) | (0.81) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.67) | (0.64) |
Please note, the imprecision that can be found in Jupiter Neurosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jupiter Neurosciences Common. Check Jupiter Neurosciences' Beneish M Score to see the likelihood of Jupiter Neurosciences' management manipulating its earnings.
Jupiter Neurosciences Workforce Analysis
Traditionally, organizations such as Jupiter Neurosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Jupiter Neurosciences within its industry.Jupiter Neurosciences Manpower Efficiency
Return on Jupiter Neurosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 609.9K | |
| Net Loss Per Executive | 348.5K | |
| Working Capital Per Employee | 660.3K | |
| Working Capital Per Executive | 377.3K |
Additional Tools for Jupiter Stock Analysis
When running Jupiter Neurosciences' price analysis, check to measure Jupiter Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jupiter Neurosciences is operating at the current time. Most of Jupiter Neurosciences' value examination focuses on studying past and present price action to predict the probability of Jupiter Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jupiter Neurosciences' price. Additionally, you may evaluate how the addition of Jupiter Neurosciences to your portfolios can decrease your overall portfolio volatility.